Cargando…
Gastric Corpus Mucosal Hyperplasia and Neuroendocrine Cell Hyperplasia, but not Spasmolytic Polypeptide-Expressing Metaplasia, Is Prevented by a Gastrin Receptor Antagonist in H(+)/K(+)ATPase Beta Subunit Knockout Mice
Proton pump inhibitor use is associated with an increased risk of gastric cancer, which may be mediated by hypergastrinemia. Spasmolytic polypeptide-expression metaplasia (SPEM) has been proposed as a precursor of gastric cancer. We have examined the effects of the gastrin receptor antagonist netaze...
Autores principales: | Aasarød, Kristin Matre, Waldum, Helge Lyder, Stunes, Astrid Kamilla, Sandvik, Arne Kristian, Flatberg, Arnar, Mjønes, Patricia, Syversen, Unni, Bakke, Ingunn, Fossmark, Reidar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037105/ https://www.ncbi.nlm.nih.gov/pubmed/32023822 http://dx.doi.org/10.3390/ijms21030927 |
Ejemplares similares
-
Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?
por: Aasarød, Kristin M., et al.
Publicado: (2021) -
Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man
por: Waldum, Helge Lyder, et al.
Publicado: (2018) -
Skeletal Effects of the Saturated 3-Thia Fatty Acid Tetradecylthioacetic Acid in Rats
por: Stunes, Astrid Kamilla, et al.
Publicado: (2011) -
The central role of gastrin in gastric cancer
por: Waldum, Helge, et al.
Publicado: (2023) -
Gastrin and Gastric Cancer
por: Waldum, Helge L., et al.
Publicado: (2017)